Medico
Unità operativa:
U.O. Gastroenterologia ed Endoscopia DigestivaArea:
Scienze MedicheEmail:
cristiano.spada@poliambulanza.it
Contatti unità operativa di appartenenza:
deg.segreteria@poliambulanza.it
Tel.: 030/3515372
DIDATTICA
Organizzazione e docenza nell’ambito di corsi base ed avanzati di formazione teorico-pratica per medici di base, specializzandi e specialisti in tecniche di endoscopia digestiva operativa nell’ambito dello “European Endoscopy Training Centre (EETC)” (Dir. Scientifico Prof. G. Costamagna, Università Cattolica del Sacro Cuore – Roma)
Docenza nell’ambito del Master Universitario di II livello in Endoscopia Digestiva, Università Cattolica del Sacro Cuore, Roma
Docenza nell’ambito del Master di Ostetricia, Università Cattolica del Sacro Cuore, Roma
Docenza nel Corso di Laurea in Medicine and Surgery (Corso di Laurea in Inglese), Università Cattolica del Sacro Cuore, Roma
Docenza nella Scuola di Specializzazione in Gastroenterologia, Università Cattolica del Sacro Cuore, Roma
È autore e coautore di oltre 100 pubblicazioni in tema di medicina endoscopica.
1. Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study with In-house blinding to determine the effect of 156 weeks of treatment with MK-0966 on the recurrence of neoplastic polyps of the large bowel in patients with a history of colorectal adenomas. (Merck & Co., Inc, USA) (2000)
2. Safety and efficacy of recombinant human Interleukin-10 (Tenovil TM) in prevention of post ERCP acute pancreatitis in subjects with increase risk. (Schering-Plough Research Institute. USA) (2002)
3. Evaluation of the M2A Patency Capsule in the GI tract (2002).
4. Performance evaluation of capsule endoscopy in the diagnosis of gluten sensitive enteropathy (GI-MA-23) (Given Imaging Ltd. Israel) (2003)
5. L’utilizzo di Macrogol e Simeticone migliora la performance della enteroscopia con videocapsula? Studio randomizzato in confronto a dieta liquida. (Promefarm) (2004)
6. Performance evaluation of the Given Patency System (GI-MA-34) (Given Imaging Ltd. Israel) (2005)
7. A multicenter randomized study to diagnose small bowel pathology using paired capsule endoscopy with two different devices- The duocaps study. (Olympus Optical Company, Europe) (2005)
8. Evaluation of the Pillcam Colon Capsule Endoscopy in the visualization of the colon (GI-MA-53) (Given Imaging Ltd. Israel) (2006)
9. Evaluation of the PillCam Colon Capsule Endoscopy (PCCE) preparation and procedure (GI- MA- 109) (Given Imaging Ltd. Israel) (2007)
10. Evaluation of a new reduced volume bowel preparation before colonoscopy (Promefarm) (2009)
11. Evaluation of the PillCam Colon 2 Capsule Endoscopy (PCCE) in the visualization of the colon (GI- MA- 201) (Given Imaging Ltd. Israel) (2009)
12. La preparazione inadeguata alla colonscopia. Quali fattori sono rilevanti? Uno studio di coorte in Italia (Promefarm 2010)
13. Immunità innata e mucosa intestinale: ruolo nella modulazione del microambiente e delle risposte dei linfociti T nelle malattie infiammatorie intestinali (Istituto Superiore di Sanità) (2011)
14. PillCam Colon Capsule and CT-colonography in the evaluation of patients with incomplete conventional colonoscopy (Given Imaging Ltd. Israel) (2011)
15. Evaluation of a new, low-volume, NaP-free protocol of preparation for capsule colonoscopy (Given Imaging Ltd. Israel and Promefarm) (2011)
16. MORDIS: Multicenter, Open, Prospective study on modified resect and discard strategy of small colonic lesions using WavStat Biopsy system. (Spectra Science) (2013)
17. CCANDY Trial (Colon Capsule for Advanced Neoplasia Diagnodtic Yield) (2014)
18. A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) versus MOVIPREP® using a 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimens in Adults (Norgine) (2015)
19. Evaluation of split low-volume vs split high-volume PEG bowel preparation for colonoscopy (2016)
20. Preparation for colonoscopy: expert recommendations and survey on the diffusion of and compliance with international guidelines in Italy. (Norgine) (2016)
21. Evaluation of PillCam SBC Capsuel Endoscopy System performance in established and suspected IBD patients to Assess System Functionality by Visualizing and Assessing the Small Bowel and Colon (PIANO Study) (Medtronic 2016)
22. Multicenter, prospective, randomized study comparing PillCam® Crohn’s capsule endoscopy to ileocolonoscopy (IC) plus MRE for detection of active CD in the small bowel and colon in subjects with known CD and mucosal disease (the BLINK study) (Medtronic 2017)
23. Prospective, Confirmatory, Multicenter Study for the Evaluation of Safety and Performance of the Interscope EndoRotor ® Endoscopic Mucosal Resection System for the Removal of Alimentary Tract Mucosa in the Colon. (Interscope Medical, Inc) (2017)
24. Prospective analysis of the accuracy of a rapid reading algorithm for small bowel capsule - Mirocam Express view evaluation - Analisi prospettica dell'accuratezza dell'algoritmo di lettura rapida per capsula dell'intestino tenue - Valutazione di Mirocam Express View (Mirocam, Intromedic, Korea) (2018)
25. HYBRID EMR - Fattibilità della tecnica di mucosectomia (EMR) ibrida per il trattamento delle lesioni colon-rettali di dimensioni comprese tra 20 e 30 mm: studio di fattibilità - Studio HYBRID EMR (Studio spontaneo) (2018)
26. Studio multicentrico, randomizzato, a gruppi paralleli di fase IV, per confrontare efficacia, sicurezza e tollerabilità di PLENVU® (preparazione per pulizia intestinale 1 L a base PEG+ASC) rispetto a SELG-ESSE® (preparazione per pulizia intestinale 4 L a base PEG) utilizzando un regime di somministrazione della dose in due giorni. (Norgine Ltd) (2018)
27. Phase IV randomized, double blind, multicenter, placebo-controlled clinical trial to evaluate the efficacy and the safety of Enterogermina (Bacillus Clausii) treating patients with Small Intestinal Bacteria Overgrowth (Sanofi) (2018)
28. 64304500CRD2001 (Trident): “A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn’s Disease (Parexel) (2018)
29. Valutazione della sicurezza e accuratezza diagnostica del sistema di colonscopia robotica Endotics nelle patologie del colon retto (Endotics) (2018)
30. InPrep: Comparison between a new low-volume PEG containing citrates and simeticone and the standard high-volume preparation (4-Liter polyethylene glycol solution) for colon cleansing in inpatients. A randomized controlled trial (2018)
31. Role of pan-endoscopy as a single bowel imaging diagnostic tool in the evaluation of low-risk symptomatic patients. A Mutlicentre European pilot trial (Medtronic. 2018)
32. A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC) – REGISTRY (Abbvie. 20118)
33. Studio randomizzato di ottimizzazione della dose per valutare l’efficacia e la sicurezza di cobitolimod in pazienti con colite ulcerosa attiva da moderata a grave (InDex Pharmaceuticals. 2018)
34. Studio sulla sicurezza a lungo termine di Entyvio (vedolizumab): uno studio di coorte, prospettico, osservazionale e internazionale che compara vedolizumab ad altri agenti biologici in pazienti affetti da colite ulcerosa o malattia di Crohn- studio PASS (Takeda. 2018)
35. LIVE Italian real-life study evaluating the long-term effectiveness of Vedolizumab for the treatment of Inflammatory Bowel Disease (IBD) (Promosso da IgIBD. 2018)
36. Valutazione del probiotico VSL#3® nel mantenimento della remissione clinica ed endoscopica nella colite ulcerosa (PROREM UC) (VSL Pharmaceuticals. 2018)
37. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Comparing Etrasimod Versus Placebo for the Treatment of Subjects With Moderately to Severely Active Ulcerative Colitis (Arena Pharmaceuticals. 2018)
38. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group,Multicenter Study Comparing Etrasimod Versus Placebo as Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. (Arena Pharmaceuticals. 2018)
39. A 52‐Week, Multicenter, Randomized, Double‐blind, Double‐dummy, Placebo and Active‐Controlled, Seamless, Adaptive, Phase 2b/3, Parallelgroup Study to Assess the Efficacy and Safety of Brazikumab in Patients with Moderately to Severely Active Crohn’s Disease (Allergan. 2018)
40. A 52‐Week, Multicenter, Randomized, Double‐blind, Double‐dummy, Placebo and Active‐Controlled, Seamless, Adaptive, Phase 2b/3, Parallelgroup Study to Assess the Efficacy and Safety of Brazikumab in Patients with Moderately to Severely Active Culcerative Colitis (Allergan. 2018)
41. RPC01-3201 / RPC01-3202; Phase III Ozanimod induction study for moderately to severely active Crohn’s disease, RPC01-3203 Ozanimod Maintenance Study and RPC01-3204 Ozanimod Open-Label Extension Study (Celgene. 2018)
Per la tutela della salute e del ben-essere del singolo, della coppia, della famiglia
Cerca il Punto Prelievi di Poliambulanza più vicino a te ed effettua le analisi di laboratorio tramite il Servizio Sanitario Nazionale o in regime privato.
Una guida pratica per le donne che scelgono di partorire in Fondazione Poliambulanza.
Tutti i servizi Welfare per le aziende che hanno a cuore la salute dei propri dipendenti
Il nuovo punto di riferimento dei bresciani.